Bharat Biotech aims to make 700 million doses of Covid-19 vaccine in 2021
The vaccine candidate, Covaxin, received emergency use approval from India's drugs regulator on Sunday. "We have four facilities coming up and we are planning (to make) around 200 million doses in Hyderabad, 500 million doses in other cities," the company's MD Krishna Ella said. The company has 20 million doses available so far, he added.
💡 newsR Knowledge: Other News Mentions
Can person with any allergy take COVID-19 shots? Know what experts sayBharat Biotech, the manufacturer of the COVID-19 vaccine said that those who have known allergies to any component of Covaxin should not take the jab.
Ocugen to seek emergency nod for Covaxin from Health CanadaBharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the..
Ocugen to seek full approval for Covaxin in US via BLA instead of EUABharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for CanadaBharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Experts question Covaxin’s high private market price as R&D was govt subsidisedExperts have questioned the rationale of high prices of Covaxin since it is based on an established technology, is domestically-produced, and it’s R&D has been..
Hyderabad IYC workers throw bike in lake as a protest against rising fuel price |Watch|Oneindia News
Credit: Oneindia Duration: 01:20Published
Monoclonal antibodies control Covid symptoms in 24 hours, says AIG chairman Dr Reddy | Oneindia News
Credit: Oneindia Duration: 01:40Published
IMA holds passing out parade | Gentleman Cadets of Cadet Training Wing Hyderabad | Oneindia News
Credit: Oneindia Duration: 02:21Published
Covishield produces more antibodies than Covaxin, finds studyCovishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by..
Central Government signs deal for 30 crore Covid jabs with Hyderabad's Biological-E | Oneindia News
Credit: Oneindia Duration: 01:15Published
You Might Like
Related videos from verified sources
Related news from verified sources